openPR Logo
Press release

Global Therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017

10-12-2017 03:07 PM CET | Health & Medicine

Press release from: MarketResearchReports.biz

Global Therapeutic landscape for Corticosteroid 11 Beta

"The Report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - 11beta-hydroxysteroid dehydrogenase type 1 is an NADPH-dependent enzyme highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. In these tissues HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. This enzyme plays an important role in obesity and insulin resistance.

Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Ophthalmology, Cardiovascular, Dermatology and Immunology which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Glaucoma, Cardiomyopathy, Cushing's Syndrome, Dementia Associated With Alzheimer's Disease, Inflammation, Intracranial Hypertension, Metabolic Syndrome, Ocular Hypertension, Open-Angle Glaucoma, Osteopenia, Psychiatric Disorders and Wounds.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/1343230

The latest report Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

View Report @ https://www.marketresearchreports.biz/reports/1343230/corticosteroid-11-beta-dehydrogenase-isozyme-1-11-beta-hydroxysteroid-dehydrogenase-1-or-short-chain-dehydrogenasereductase-family-26c-member-1-or-hsd11b1-or-ec-111146-pipeline-review-h2-2017-market-research-reports

Scope

- The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects
- The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 - Pipeline Review, H2 2017 here

News-ID: 770813 • Views: 168

More Releases from MarketResearchReports.biz

Global Automotive Augmented Reality and Virtual Reality Market Breakdown Data by …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Augmented Reality and Virtual Reality Market Insights, Forecast to 2025” Augmented reality (AR) is a technology that adds on or layers digital media, such as touch feedback, graphics, 3D models, and sound, on a real world environment to enhance user experience and interaction. Virtual reality (VR) is a computer simulated reality that is achieved through replicating an environment
Global Artificial Intelligence in Transportation Market Breakdown Data by Region …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Artificial Intelligence in Transportation Market Insights, Forecast to 2025” Global Artificial Intelligence in Transportation market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size for Artificial
Global Automotive Wind Tunnel Testing Equipment Market Forecast to 2025: By Prod …
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Wind Tunnel Testing Equipment Market Insights, Forecast to 2025” Global Automotive Wind Tunnel Testing Equipment market size will reach million US$ by 2025, from million US$ in 2017, at a CAGR of during the forecast period. In this study, 2017 has been considered as the base year and 2018-2025 as the forecast period to estimate the market size
Global Automotive Beauty Industry Analysis and Forecast 2018-2025
MarketResearchReports.Biz has recently announced the Latest industry research report on: “Global Automotive Beauty Market Insights, Forecast to 2025” This industry study presents the global Automotive Beauty market size, historical breakdown data (2013-2018) and forecast (2018-2025). The Automotive Beauty production, revenue and market share by manufacturers, key regions and type; The consumption of Automotive Beauty in volume terms are also provided for major countries (or regions), and for each application and product

All 5 Releases